Which Acute Ischemic Stroke Patients Are Fast Progressors?: Results From the ESCAPE Trial Control Arm.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
05 2021
Historique:
pubmed: 6 4 2021
medline: 5 1 2022
entrez: 5 4 2021
Statut: ppublish

Résumé

Fast infarct progression in acute ischemic stroke has a severe impact on patient prognosis and benefit of endovascular thrombectomy. In this post hoc analysis of the ESCAPE trial (Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke), we identified acute ischemic stroke patients with rapid infarct growth and investigated their baseline clinical and imaging characteristics. Control arm patients were included if they had follow-up imaging at 2-8 hours without substantial recanalization, and if their baseline Alberta Stroke Program Early CT Score was ≥9. Fast infarct progression was defined as Alberta Stroke Program Early CT Score decay ≥3 points from baseline to 2- to 8-hour follow-up imaging. Clinical and imaging baseline characteristics were compared between fast progressors and other patients, and occlusion site and collateral flow patterns were assessed in detail. Fast infarct progression occurred in 15 of 43 included patients (34.9%). Fast progressors had worse collaterals (poor in 3/15 [20%] versus 0/28 patients, Most patients with fast infarct progression had terminal carotid occlusions and impaired collateral flow via the anterior or posterior cerebral artery, indicating that occlusion location and intracranial vascular anatomy are relevant for infarct progression.

Sections du résumé

BACKGROUND AND PURPOSE
Fast infarct progression in acute ischemic stroke has a severe impact on patient prognosis and benefit of endovascular thrombectomy. In this post hoc analysis of the ESCAPE trial (Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke), we identified acute ischemic stroke patients with rapid infarct growth and investigated their baseline clinical and imaging characteristics.
METHODS
Control arm patients were included if they had follow-up imaging at 2-8 hours without substantial recanalization, and if their baseline Alberta Stroke Program Early CT Score was ≥9. Fast infarct progression was defined as Alberta Stroke Program Early CT Score decay ≥3 points from baseline to 2- to 8-hour follow-up imaging. Clinical and imaging baseline characteristics were compared between fast progressors and other patients, and occlusion site and collateral flow patterns were assessed in detail.
RESULTS
Fast infarct progression occurred in 15 of 43 included patients (34.9%). Fast progressors had worse collaterals (poor in 3/15 [20%] versus 0/28 patients,
CONCLUSIONS
Most patients with fast infarct progression had terminal carotid occlusions and impaired collateral flow via the anterior or posterior cerebral artery, indicating that occlusion location and intracranial vascular anatomy are relevant for infarct progression.

Identifiants

pubmed: 33813863
doi: 10.1161/STROKEAHA.120.032950
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1847-1850

Auteurs

Johanna M Ospel (JM)

Clinical Neurosciences (J.M.O., M.D.H., A.M.D., B.K.M., A.M., M.G.), University of Calgary, Canada.
Radiology, University Hospital of Basel, Basel, Switzerland (J.M.O.).

Michael D Hill (MD)

Clinical Neurosciences (J.M.O., M.D.H., A.M.D., B.K.M., A.M., M.G.), University of Calgary, Canada.
Radiology (M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Manon Kappelhof (M)

UMC Amsterdam, the Netherlands (M.K.).

Andrew M Demchuk (AM)

Clinical Neurosciences (J.M.O., M.D.H., A.M.D., B.K.M., A.M., M.G.), University of Calgary, Canada.
Radiology (M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Bijoy K Menon (BK)

Clinical Neurosciences (J.M.O., M.D.H., A.M.D., B.K.M., A.M., M.G.), University of Calgary, Canada.
Radiology (M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Arnuv Mayank (A)

Clinical Neurosciences (J.M.O., M.D.H., A.M.D., B.K.M., A.M., M.G.), University of Calgary, Canada.

Dar Dowlatshahi (D)

Neurology, University of Ottawa, Ottawa, Canada (D.D.).

Don Frei (D)

Swedish Medical Center, Colorado Neurological Institute, Denver (D.F.).

Jeremy L Rempel (JL)

Radiology, University of Alberta, Edmonton, Canada (J.L.R.).

Blaise Baxter (B)

Lehigh Valley Health Network, Allentown, PA (B.B.).

Mayank Goyal (M)

Clinical Neurosciences (J.M.O., M.D.H., A.M.D., B.K.M., A.M., M.G.), University of Calgary, Canada.
Radiology (M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH